Oncology Support Medications

10 · 20mg

Formulated to manage hormone-receptor-positive breast cancer and to support treatment outcomes through oestrogen receptor inhibition.

1mg

Arimidex is developed to target hormone-dependent breast cancer and is formulated to alleviate tumour progression.

1mg

Indicated to help manage oestrogen-dependent conditions by supporting the suppression of excess hormone production in postmenopausal patients.

2.5mg

Femara is indicated for the treatment of hormone-dependent breast cancer and utilized to alleviate tumour growth in post-menopausal women.

50mg

Designed to target tumour growth, indicated to manage advanced prostate cancer effectively.

2.5mg

Utilized to manage autoimmune responses and indicated to alleviate inflammation-related tissue damage effectively.

2 · 5mg

Utilized to manage specific types of blood cancers, formulated to slow the progression of malignant cellular growth in the lymphatic system.

50mg

Utilized to target malignant neoplasms to alleviate disease progression and cell proliferation.

500mg

Developed to alleviate conditions involving abnormal blood cell growth to address long-term stability and symptom control.

2mg

Formulated to address malignant cell proliferation by supporting the alkylation of DNA and inhibiting cellular replication.

500mg

Developed to target cancerous growths by utilizing systemic conversion to therapeutic agents that inhibit DNA synthesis.

1 · 5%

Utilized to target actinic keratosis and intended to support the reduction of cancerous skin cell proliferation.

150 · 200mg

Utilized to target specific protein kinases in chronic myeloid leukaemia and designed to alleviate disease progression in affected patients.

50mg

Utilized to target kinase-positive leukaemias and formulated to support the mitigation of malignant cell growth in patients.

250mg

Developed to target prostate cancer progression, this medication is utilized to alleviate hormonal signals that support tumour growth.

25mg

Developed to target oestrogen production and indicated to support cancer treatment, this inhibitor is utilized to address hormone-sensitive malignancies.

50 · 100mg

Formulated to alleviate symptoms of multiple myeloma to support patient stabilization.

200mg

Developed to address carcinoma growth to alleviate tumour progression.

10mg

Indicated to address haematological malignancies to support cancer remission.

100 · 400mg

Designed to target cancer cells to alleviate disease progression.

5 · 10mg

Developed to target cancer cells to support tumour growth suppression.

250mg

Formulated to target prostate cancer to alleviate hormonal progression.